Evaluation of Pharmacist-Managed Dabigatran in an Inpatient Setting

Annals of Pharmacotherapy

Volumn 47, Issue 12, 2013, Pages 1649-1653

  Tedders, Kristen M ^a   Lucey, Michael F ^a   Edwin, Stephanie B ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

anticoagulation; dabigatran; intervention; pharmacist

Indexed keywords

ANTICOAGULANT AGENT; DABIGATRAN; HEPARIN;

AGED; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG EFFICACY; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; KIDNEY DYSFUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PHARMACIST; PRIORITY JOURNAL; RECTUM HEMORRHAGE;

ANTICOAGULATION; DABIGATRAN; INTERVENTION; PHARMACIST;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; DRUG MONITORING; FEMALE; HOSPITALIZATION; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PHARMACISTS; PHARMACY SERVICE, HOSPITAL;

EID: 84891680355     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013508643     Document Type: Article

References (12)

1. Jones M,McEwan P,Morgan CLet al.Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvular atrial fibrillation: a record linkage study in a large British population.Heart. 2005;91:472-477.
2. Newman DH,Zhitomirsky I.The prevalence of nontherapeutic and dangerous international normalized ratios among patients receiving warfarin in the emergency department.Ann Emerg Med. 2006;48:182-189.
3. Blommel ML,Blommel AL.Dabigatran etexilate: a novel oral direct thrombin inhibitor.Am J Health Syst Pharm. 2011;68:1506-1519.
4. Pradaxa (dabigatran) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2012:.
5. You JJ,Singer DE,Howard PAet al.Antithrombotic therapy for atrial fibrillation.Chest. 2012;141:e531S-e575S.
6. Connolly SJ,Ezekowitz MD,Yusuf Set al.Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009;361:1139-1151.
7. The Joint Commission. 2013National Patient Safety Goals. http://www.jointcommission.org/assets/1/18/NPSG_Chapter_Jan2013_HAP.pdf. Accessed June 6, 2013.
8. Budnitz DS,Lovegrove MC,Shehab Net al.Emergency hospitalizations for adverse drug events in older Americans.N Eng J Med. 2011;365:2002-2012.
9. Schillig J,Kaatz S,Hudson Met al.Clinical and safety impact of an inpatient pharmacist-directed anticoagulation service.J Hosp Med. 2011;6:322-328.
10. Wong YM,Quek YN,Tay JCet al.Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiation and titration.J Clin Pharm Ther. 2010;36:585-591.
11. Dager WE,Branch JM,King JHet al.Optimization of inpatient warfarin therapy: impact of a daily consultation by a pharmacist-managed anticoagulation service.Ann Pharmacother. 2000;34:567-572.
12. MooreTJCohenMRFurbergCD. QuarterWatch: anticoagulants the leading reported drug risk in 2011. http://www.ismp.org/quarterwatch/pdfs/2011Q4.pdf. Accessed May 17, 2013.